Reports
Sale
Global Anticoagulants Market Share, Size, Trends, Growth, Report, Price, Analysis, Demand, Forecast: By Drug Class: Novel Oral Anticoagulants (NOACs), Heparin and Low Molecular Weight Heparin (LMWH), Vitamin K Antagonist; By Application; By Route of Administration; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Global Anticoagulants Market Outlook
The global anti coagulants market size attained a value of USD 37.65 billion in 2023 driven by growing lifestyle risks like diabetes and obesity, along with the growing health awareness among the public, currently require better and efficient treatments. The market is anticipated to grow at a CAGR of 11.5% during the forecast period of 2024-2032 to attain a value of USD 97.18 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America has a Significant Market Share in the Anticoagulants Industry
North America is one of the major markets in the anticoagulants industry. This can be attributed to the increase in the incidence rate of cardiovascular diseases in North America. According to Centres for Disease Control and Prevention, one in every 4 deaths is caused by heart disease, i.e., about 655,000 Americans die from heart disease each year. Further, a well-established healthcare infrastructure, along with the presence of key pharma and biotech companies, is supporting the entire regional market's expansion to a great extent.
Rising Cases of Cardiovascular Diseases in Europe and the Asia Pacific to Augment the Market Growth
Europe is also a significant contributor to the anticoagulants industry. According to the European Society of Cardiology (ESC), the region witnesses more than 11 million new cases of cardiovascular diseases (CVD) on the whole every year, as per 2019 statistics. In the EU, about 49 million people are currently living with this condition. Further, as per ESC, CVD is the leading cause of death in Europe, accounting for about 45% of all deaths and 37% in the EU. Meanwhile, major countries in the Asia Pacific, such as China, are also rising cases of CVD. China is witnessing an increasing mortality rate attributed to CVD. In 2016, as reported by the Journal of Geriatric Cardiology, cardiovascular disease (CVD) was the top cause of mortality in both rural and urban areas, accounting for 45.50% and 43.16% of all deaths, respectively. This is likely to make China an emerging market for anticoagulants in the forecast period.
Anticoagulants: Market Segmentation
Anticoagulants are referred to as those drugs that prevent the formation of blood clots. They're given to those who have a high risk of blood clots to help them avoid catastrophic diseases, including strokes and heart attacks. Anticoagulants act by inhibiting the process that causes the formation of blood clots. They are also known as "blood thinners".
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
On the basis of drug class, the market can be classified into:
- Novel Oral Anticoagulants (NOACs)
- Heparin and Low Molecular Weight Heparin (LMWH)
- Vitamin K Antagonist
The market can be broadly categorised on the basis of its applications into:
- Atrial Fibrillation/Myocardial Infarction (Heart Attack)
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism
- Others
The EMR report looks into the regional markets of anticoagulants like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Lifestyle Risks Like Obesity and Diabetes to Boost the Anticoagulants Industry
The growing lifestyle risks like diabetes and obesity, along with the growing health awareness among the public, currently require better and efficient treatments. The introduction of NOACs has resulted in a significant increase in anticoagulant use and expenditure. The development of pharmaceuticals and therapeutic companies is boosting the production and efficiency of anticoagulants. This is augmenting the market growth of anticoagulants. The risks and threats for health posed by COVID-19 have boosted investments in the anticoagulant industry. The growing healthcare expenditure by the government, along with key market players, is a huge driving force for the market. There are strict government regulations attributed to the safety and dosage of anticoagulants. The FDA approval of anticoagulants usage for paediatric heart patients in 2019 is also a huge boost to the industry.
Key Industry Players in the Global Anticoagulants Market
The report presents a detailed analysis of the following key players in the global anticoagulants market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Johnson & Johnson Services, Inc.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company, Limited
- GlaxoSmithKline plc
- Aspen Pharmacare Holdings Limited
- Pfizer Inc.
- Portola Pharmaceuticals, Inc.
- Others
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Application |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Anticoagulants Market Overview
3.1 Global Anticoagulants Market Historical Value (2017-2023)
3.2 Global Anticoagulants Market Forecast Value (2024-2032)
4 Global Anticoagulants Market Landscape
4.1 Global Anticoagulants Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Anticoagulants Product Landscape
4.2.1 Analysis by Drug Class
4.2.2 Analysis by Application
4.2.3 Analysis by Route of Administration
4.2.4 Analysis by Distribution Channel
5 Global Anticoagulants Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Anticoagulants Market Segmentation
6.1 Global Anticoagulants Market by Drug Class
6.1.1 Market Overview
6.1.2 Novel Oral Anticoagulants (NOACs)
6.1.3 Heparin and Low Molecular Weight Heparin (LMWH)
6.1.4 Vitamin K Antagonist
6.2 Global Anticoagulants Market by Application
6.2.1 Market Overview
6.2.2 Atrial Fibrillation/Myocardial Infarction (Heart Attack)
6.2.3 Deep Vein Thrombosis (DVT)
6.2.4 Pulmonary Embolism
6.2.5 Others
6.3 Global Anticoagulants Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral Anticoagulants
6.3.3 Injectable Anticoagulants
6.4 Global Anticoagulants Market by Distribution Channel
6.4.1 Market Overview
6.4.2 Oral Anticoagulants
6.4.3 Injectable Anticoagulants
6.5 Global Anticoagulants Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Anticoagulants Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Anticoagulants Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Anticoagulants Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Anticoagulants Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Anticoagulants Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Johnson & Johnson Services, Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Bayer AG
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Boehringer Ingelheim International GmbH
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Bristol-Myers Squibb Company
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Daiichi Sankyo Company, Limited
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 GlaxoSmithKline plc
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Aspen Pharmacare Holdings Limited
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Pfizer Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Portola Pharmaceuticals, Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 AstraZeneca
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Aspen Holdings
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Celgene
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Armetheon, Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
18 Global Anticoagulants Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
Globally, anticoagulants market reached a value of USD 37.65 billion in 2023.
The market is projected to expand at a CAGR of 11.5% from 2024 to 2032, growing to USD 97.18 billion by 2032.
The growing incidence of cardiovascular diseases, growing lifestyle risks, and growing health awareness are leading the market growth.
The adoption of more efficient and safer anticoagulants like NOACs is expected to influence the market over the forecast period.
The major regions in the market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The different drug classes of anticoagulants are novel oral anticoagulants (NOACs), heparin and low molecular weight heparin (LMWH), vitamin K antagonist.
The anticoagulants find its applications in the treatment of atrial fibrillation/myocardial infarction (heart attack), and deep vein thrombosis (DVT), and pulmonary embolism, among others.
The major players in the industry are Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Aspen Pharmacare Holdings Limited, Pfizer Inc., and Portola Pharmaceuticals, Inc., among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5999
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 7999
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9999
$5999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER